Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)

NCT04640025 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04640025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
March 10, 2021
Completion date
May 11, 2026
Enrollment
18 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease, myelofibrosis, postlung transplant (bronchiolitis obliterans)